RxGen Prime 2 Supporting Studies
In Vitro • Study 1
Compared RxGen Prime2 to control for its ability to inhibit cathepsin-G by measuring with a spectrofluoro-meter the amount of fluorescence labelled protein degraded after exposure to RxGen Prime2 at differing concentrations
RxGen Prime2 inhibited at 0.014% half of the Cathepsin-G and at 0.1% inhibited 100% Cathepsin-G function (See Diagram 6)
In Vitro • Study 2
Normal human skin keratinocytes incubated two days treated with RxGen Prime2 0.8% compared to ASA 0.01% to inhibit Interlukin-6 after exposure to UVB 16mj/cm IL6 measured with ELISA.
RxGen Prime2 decreased inflammatory IL-6 by 75% compared to ASA at 67% (See Diagram 7).
In Vitro • Study 3
Normal human skin fibroblast incubated two days treated with RxGen Prime2 0.5% compared to Dexamethasone 10.7m to inhibit MMP-1 (proteinase) synthesis after exposure to IR Radiation 950j/cm measured with ELISA.
RxGen Prime2 decreased MMP-1 synthesis 19% compared to steroid at 100% (See Diagram 8).
In Vitro • Study 4
Normal human skin fibroblast incubated two days treated with RxGen Prime2 0.1% & 0.5% compared to TGF-B 10ng/ml to stimulate fibronectin & Elastin fiber Synthesis measured with immuno-labelling.
RxGen Prime2 increased synthesis of fibronectin 6.8% and elastin 74% compared to TGF-B at 16.9% & 94% respectively (See Diagram 9).
20 women use RxGen Prime2 twice daily on one side of the face and one forearm for 28 days. A cutometer was used to measure forearm skin elasticity and a TOP-blue 3D scanner was used to evaluate crow’s feet wrinkles of the face lateral to the eye compared to the control side which was untreated.
RxGen Prime2 treated arm skin improved elasticity and firmness by 11.9% over the control arm. Split face studies showed a decrease in crow’s feet wrinkle volume after treatment with RxGen Prime2 of 25% when compared to the control side (See Diagram 10 & 11).